who enables release over time? we do.
date: July 8-12, 2024
location: Bologna Congressi, Bologna, Italy
booth: Booth #26
Ashland solvers’ expertise in controlled release polymers results in tailored release profiles for injectable and oral drugs that meet your requirements for active pharmaceutical ingredient delivery.
key products
benecel™ xrf hpmc are fine particle grades designed for optimal performance in large-scale, high speed tableting. This product provides better powder flowability, produces robust tablets under high-throughput continuous manufacturing conditions and for challenging multi-layer sustained release tablets, and with lower nitrosamine levels, improves formulation stability by minimizing the potential for interaction between API and excipients that results in NDMA.
viatel™ bioresorbable polymers control release over time. These polymers are the building blocks for developing long-acting injectable depots, an established technology to improve therapeutic efficacy and patient compliance. All viatel™ bioresorbable polymers can be custom produced.
viatel™ ultrapure high-purity bioresorbable polymers are long-acting injectables and implants that offer improved stability and achieve longer, more consistent drug release profiles; they are better suited for sensitive drug compounds in long-acting injectables and implants (LAII).
klucel™ xtend hpc has been shown to match the release profile of widely used hypromellose controlled release formulations at half the polymer concentration. The highly reduced polymer concentration achievable with klucel™ xtend HPC offers the possibility of smaller pills or higher dosage. This product is designed to deliver unsurpassed process versatility and release profile efficiency.
Visit booth 26 to learn more about our key products and other controlled release polymers that will help support your formulations.
Visit with us at CRS to learn about the ways we are always solving:
Long Acting lnjectables: Microsphere Design, Development and Scale-Up Using Chroniject™ with Viatel™ Lactide / Glycolide Bioresorbable Polymers
date: Monday, July 8, 2024
time: 1:00 p.m. - 5:00 p.m.
room: Magenta B.
This educational workshop will focus on development and scale-up of long-acting injectable microspheres. Attendees will have an opportunity to learn about the selection of polymers and optimization of long-acting microsphere formulations with releases ranging from weeks to one year. Ashland and Oakwood Labs will present together, respectively discussing how viatel™ bioresorbable polymers are optimized in various parenteral formulations and Oakwood Labs' Chroniject™ microsphere technology platform that offers reproducible, scalable, and consistent critical quality attributes under cGMP for multiple therapeutic indications. Ashland will show how understanding the chemistry and versatility of viatel™ polymers helps solve challenges in controlled drug release formulations and advanced drug delivery. Data on NEW viatel™ ultrapure bioresorbable polymers will also be presented to showcase the benefit of ultra-low residual monomer specifications. Oakwood Labs will present case studies using different active pharmaceutical ingredients (API) and varying process/polymer parameters to highlight formulation development through scale-up alongside challenges and solutions.
Brad Minrovic, PhD
technical account manager, pharmaceuticals, Life Sciences
Risperidone-Loaded Sustained Release Implants – From Benchtop to Commercial Scale
date: Tuesday, July 9, 2024
time: 9:00 a.m.
room: Sala Italia
introduction: Long acting injectables (LAI’s) frequently utilize bio-resorbable polymers to control the release of active pharmaceutical ingredients via tunable degradation rates. One commonly used bioresorbable polymer is poly (lactic-co-glycolic acid), or PLGA because they allow for tuning of co-monomer ratio, molecular weight, and end group to meet a characteristic degradation rate1. Degradation rates, geometry and, API characteristics such as hydrophobicity and loading determine the pharmacokinetic profile of the long-acting injectable product2. One less studied aspect of PLGA bio-resorbable polymers is the effect monomers can have on the degradation rate and drug stability. The purpose of this study is to examine the effects monomer has on long-acting injectable formulations release and stability.
authors: Patrick Duffy, R&D team leader, bioresorbable polymers, Life Sciences
©, Ashland. All rights reserved.
